BOLT · Bolt Biotherapeutics, Inc.
$3.35
+0.14 (+4.36%)
At close · Aug 14
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Under our current operating plans, we believe our cash and cash equivalents and marketable securities of $18.1 million as of June 30, 2026 may be sufficient to fund our operations into first quarter 2027. As a result, we have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the issuance of the unaudited condensed consolidated financial statements.”View the 10-Q filed Aug 11, 2026
Market Cap
$6.45M
Shares
1.93M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| William P. Quinn | President, Chief Executive Officer and Chief Financial Officer | $4,558,368 |
| Grant Yonehiro | Chief Operating Officer | $4,007,443 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Randall C. Schatzman | Former Chief Executive Officer | $1,438,898 |
| William P. Quinn | President, Chief Executive Officer and Chief Financial Officer | $1,203,328 |
| Grant Yonehiro | Chief Operating Officer | $948,414 |
| Edith Perez | Former Chief Medical Officer | $882,144 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Randall C. Schatzman | Former Chief Executive Officer | $1,750,629 |
| Edith Perez | Former Chief Medical Officer | $982,715 |
| William P. Quinn | President, Chief Executive Officer and Chief Financial Officer | $912,175 |
| Grant Yonehiro | Chief Operating Officer | $839,504 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Randall C. Schatzman | Chief Executive Officer | $2,235,412 |
| Edith Perez | Chief Medical Officer | $1,137,019 |
| William P. Quinn | Chief Financial Officer | $1,063,259 |
| Grant Yonehiro | Chief Business Officer | $968,768 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Randall C. Schatzman | Chief Executive Officer | $5,935,603 |
| David Dornan | Former Chief Scientific Officer | $2,231,676 |
| Edith Perez | Chief Medical Officer | $2,128,771 |
| William P. Quinn | Chief Financial Officer | $2,065,131 |
| Grant Yonehiro | Chief Business Officer | $2,021,431 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Randall C. Schatzman | Chief Executive Officer | $1,603,291 |
| Edith Perez | Chief Medical Officer | $1,268,840 |
| William P. Quinn | Chief Financial Officer | $938,752 |
| David Dornan | Former Chief Scientific Officer | $576,781 |
| Grant Yonehiro | Chief Business Officer | $572,203 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Dr. Mahendra Shah, Ph.D. | member of the Company's Board of Directors | Resigned | 2024-12-23 |
| Jakob Dupont, M.D., Ph.D. | Class II member of the Board | Appointed | 2024-09-04 |
| Frank D. Lee | member of the Board | Resigned | 2024-09-04 |
| James Healy, M.D., Ph.D. | member of the Company's Board of Directors | Resigned | 2024-09-04 |
| Edith A. Perez, M.D. | Chief Medical Officer | Resigned | 2024-05-14 |
| Randall C. Schatzman, Ph.D. | Chief Executive Officer | Resigned | 2024-05-14 |
| Randall C. Schatzman, Ph.D. | member of the Board | Resigned | 2024-05-14 |
| Edgar G. Engleman, M.D. | member of the Company's Board of Directors | Resigned | 2024-05-14 |
| Laura Berner | Class I director | Appointed | 2022-12-14 |
| David Dornan, Ph.D. | Chief Scientific Officer | Resigned | 2022-03-04 |